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BACKGROUND. Monocarboxylate transporter 2 (MCT2) is a transmembrane protein
involved in the transport of monocarboxylates such as pyruvate and lactate. In a previous
study we described overexpression of MCT2 in prostate carcinoma raising the hypothesis of
using MCT2 as a possible biomarker in prostate cancer.
With the present study we aimed to compare the pattern of expression of MCT2 and alpha-
methylacyl-CoA racemase (AMACR), in prostate carcinoma, PIN lesions, non-neoplastic
prostate tissue, and normal prostate and compare their sensitivity and specificity. Also, we
wanted to evaluate the value of using MCT2 in combination with AMACR and the negative
markers 34bE12 or p63 to detect prostate cancer.
METHODS. A total of 349 cases, including prostate carcinoma, non-neoplastic prostate tis-
sue and PIN lesions, from radical prostatectomies were examined by immunohistochemistry
for AMACR, MCT2, p63, and 34bE12, using tissue microarrays (TMAs). Normal prostate
from radical cystoprostatectomy was also studied.
RESULTS. Our study revealed that MCT2, similarly to AMACR, was consistently expressed
in prostate cancer regardless of the Gleason score. In combination with AMACR and p63 or
34bE12, MCT2 helped to improve the diagnosis of prostate carcinoma. Also, overexpression
of MCT2 as well as AMACR in PIN lesions may indicate the involvement of these two pro-
teins in prostate cancer initiation.
CONCLUSIONS. We provided evidence for the presence of MCT2 in prostate cancer, selec-
tively labeling malignant glands. Importantly, assessment of MCT2 together with AMACR,
along with the negative markers, highly increases the accuracy in prostate cancer diagnosis.
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INTRODUCTION
Worldwide, prostate cancer is the second most
common malignancy in men after lung cancer [1].
Diagnosis of prostate cancer glands can sometimes
present a diagnostic challenge for pathologists, since,
prostate carcinoma can mimic benign prostate glands
[2] and the architectural or cytologic clues for the
diagnosis of carcinoma may not always be seen in
small foci of suspicious glands. Also, diagnosis of
prostate cancer can be difficult in needle biopsies or
in minimal residual cancer of radical prostatectomies,
presenting one of the major challenges in surgical pa-
thology. Underdiagnosis of a small focus of prostatic
adenocarcinoma or overdiagnosis of a benign lesion
mimicking cancer is not uncommon and can cause
unfortunate consequences for patients and is a liabili-
ty for pathologists. Therefore, it would be of great
importance and usefulness to identify molecular
markers with high sensitivity and specificity for pros-
tate carcinoma.
Monocarboxylate transporters (MCTs) are trans-
membrane proteins which facilitate the membrane
transport of important monocarboxylates, such as py-
ruvate and lactate. In glycolytic tumors, they promote
the efflux of lactic acid, being important players in
the maintenance of the tumor intracellular pH [3,4].
In a first study we assessed the immunoexpression of
MCTs 1, 2, 4 and their protein chaperones in a well
characterized prostate carcinoma series [5]. This study
revealed a significant increase of MCT2 expression in
tumor cells with a predominance of the strong score,
which means that we could distinguish between
MCT2 expression in tumor tissue from the expression
of this protein in non-neoplastic tissue.
In the same study [5], we noted that MCT2 staining
was very similar to AMACR (alpha-methylacyl-CoA
racemase), an enzyme currently used in prostate can-
cer diagnosis, which is a peroxisomal and mitochon-
drial enzyme that was found to be up-regulated in
prostate cancer [6–8]. AMACR plays an important
role in bile acid biosynthesis and b-oxidation of
branched-chain fatty acids and mediates the intercon-
version of (R) and (S)-2-methyl-branched-chain fatty
acyl-CoAs [9,10], however, the biological significance
of its expression in tumorigenesis is still not
elucidated.
Some studies suggested that the use of AMACR as
a positive marker alone may be misleading since ex-
pression of AMACR might be seen in benign glands,
and non-malignant lesions [11]. Therefore, other stud-
ies report the use of AMACR as a positive marker
along with the basal cell-specific negative markers
34bE12 and p63, which are absent in the vast majority
of prostate carcinomas, to enhance the diagnostic
accuracy and reduce the chance of misdiagnosis [12].
34bE12 is a high-molecular-weight cytokeratin that is
expressed in the cytoplasm of basal cells rather than
in luminal or secretory cells [13]; p63 has selective
expression in the basal cell compartment of various
epithelial tissues and has high sensitivity in identify-
ing the nuclei of basal cells in benign prostatic lesions
[14–16].
This study aims to compare the sensitivity and
specificity of MCT2 and AMACR in recognizing pros-
tate cancer, by analyzing the immunohistochemical
expression of both markers in a large series of pros-
tate samples, including normal prostate, adjacent
non-neoplastic tissue, PIN lesions and tumor tissues,
and assess their clinico-pathological value. Also, we
aimed to measure the sensitivity and specificity
of combining MCT2 and AMACR as positive
markers with the negative markers p63 and 34bE12,
using tissue microarrays (TMAs), which recapitulate
the small problematic foci of glandular proliferation
that are generally encountered in prostatic biopsy
specimens.
MATERIALSANDMETHODS
CaseSelectionandTissueMicroarrayConstruction
Prostate samples were obtained from 349 patients
with prostate carcinoma (including adjacent non-
neoplastic tissues, PIN lesions, and primary tumors),
with a median age of 64 years (range 46–74) selected
from a cohort of patients who underwent radical pro-
statectomy in Centro Hospitalar do Porto—Portugal
as a primary therapy (no preceding hormonal or radi-
ation therapy) for clinically localized prostate cancer
between 1993 and 2010. Benign prostate tissue was
obtained from cystoprostatectomy specimens.
TMAs were constructed as previously reported [5].
Tumors were staged using the 2010 pTNM AJCC clas-
sification [17], which includes extra-prostatic exten-
sion and graded using the Gleason grading system
2005 [18].
Although there is no universal method of sampling
prostate cancer tissue for immunohistochemistry
slides, using either standard slides or TMAs, the
histological features of the sampled areas that we
sampled were representative of the final Gleason
score for the case.
Immunohistochemistry
MCT2, AMACR, p63, and 34bE12 detection. Immu-
nohistochemistry for MCT2, AMACR, p63, and
34bE12 was performed according to avidin–biotin–
peroxidase complex principle with the primary
2 Pe¤ rtega-Gomeset al.
The Prostate
antibody for MCT2 (sc-14926, Santa Cruz Biotechnolo-
gy, Santa Cruz, CA), AMACR (504R-16, Cell Marque),
p63 (MS-1084-P, Neomarkers), and 34bE12 (334M-8,
Cell Marque) diluted 1:200, 1:50, 1:100, and 1:100,
respectively. Negative controls were performed by
omitting of the primary antibody. Normal kidney was
used as positive control for MCT2, AMACR, and p63.
Human skin was used as 34bE12 positive control.
Tissue sections were counterstained with hematox-
ylin and permanently mounted.
ImmunohistochemicalEvaluation
All samples were scored for AMACR and MCT2
protein expression intensity. Protein expression was
scored as negative (score ¼ 0), weak (score ¼ 1),
moderate (score ¼ 2), or strong (score ¼ 3). Moderate
or strong staining intensity was considered positive
(score ¼ 2 or 3) as previously described for AMACR
[19].
Each case positive for AMACR and MCT2 was
also evaluated for the percentage of glands/cells that
stained for AMACR and MCT2 and scored as: <5%,
5–50%, and >50%.
Positive immunohistochemical staining for 34bE12
and p63 was defined as nuclear reactivity for p63
and cytoplasmic positivity for 34bE12 [12,20].
Criteria for interpretation of the antibody combina-
tion were as follows: cases were considered true-
positive when 34bE12/p63 and AMACR, all of
the three antibodies stained as for a malignant lesion,
that is, 34bE12 and p63 stains absent and AMACR
present. Using the combination with p63/AMACR/
MCT2 or 34bE12/AMACR/MCT2 true-positive was
considered when p63 and 34bE12 stains were absent
but AMACR and/or MCT2 stains were present [20].
Each reaction was observed by two experienced
pathologist (J.R.V. and C.L.), without prior knowl-
edge of associated clinical or pathology staining
information. Discordant results were discussed in a
double-head microscope (J.R.V. and C.L.).
StatisticalAnalysis
Statistical analysis was performed using the SPSS
statistical software (version 17.0, SPSS Inc., Chicago,
IL). All comparisons were examined for statistical
significance using Pearson’s chi-square (x2) test, being
the threshold for significance P < 0.05.
RESULTS
Prostate samples were organized into TMAs,
including 349 neoplastic tissues, 40 PIN lesions,
203 non-neoplastic, and 13 normal prostate cases
from cystoprostatectomy were analyzed for MCT2,
AMACR, 34bE12, and p63 immunohistochemical
expression.
Figure 1 summarizes MCT2 and AMACR expres-
sions in normal prostate, adjacent non-neoplastic tu-
mor tissue, PIN lesions and primary tumor tissues.
For the expression of both markers, AMACR and
MCT2, we can observe a significant increase in tumor
tissues and PIN lesions compared to normal prostate
and non-neoplastic tissue samples (P < 0.001). Nor-
mal prostate samples were both negative for MCT2
and AMACR expressions. From 203 non-neoplastic
samples, 14 stained for MCT2 (6.9%) and 12 for
AMACR (5.9%). Both proteins showed overexpres-
sion in PIN lesions (77.5% for both). From the 349
malignant cases, 230 (65.9%) stained for MCT2 and
270 (77.4%) for AMACR.
Figure 2 shows representative immunohistochemi-
cal reactions for MCT2, AMACR, p63, and 34bE12
in normal prostate tissue (Fig. 2A, D, G, and J), PIN
lesions (Fig. 2B, E, H and K, respectively), and tumor
(Fig. 2C, F, I and L, respectively). The staining ob-
served for MCT2 was very similar to that observed
for AMACR. In most cases, adenocarcinomas showed
moderate to strong staining in the majority of tumor
cells for both proteins. Expression was uniformly
cytoplasmic with a typical fine granular pattern.
Nuclear staining of p63 and cytoplasmic staining for
34bE12 were confined to basal cells in normal prostate
tissue (Fig. 2G and J, respectively).
Fig. 1. Frequency of MCT2 and AMACR expressions in normal
prostate tissue, non-neoplastic tissue, PIN lesions, and tumor tis-
sue samples.
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To assess if the staining extension pattern of MCT2
and AMACR in tumor tissues is associated with
Gleason score, we compared the extension distribu-
tion of MCT2 and AMACR positivity in all Gleason
grades (Tables I and II, respectively). We noted that
regardless Gleason score, the diffuse overexpression
(>50% of tumor stained) of AMACR and MCT2 pre-
dominated and was observed in 65.5% and 57.4% of
the cases, respectively.
Assessment of associations between MCT2 and
AMACR expressions and the clinico-pathological
data revealed no significant associations with Gleason
score, pathological stage, patients’ age, or preopera-
tive serum specific antigen, perineural invasion, or
biochemical recurrence (data not shown) as it was
already observed for MCT2 using a different scoring
methodology [5].
Specificity and sensitivity to detect tumor were
calculated for the markers individually (Table III), as
well as within the triple combinations (Table IV).
From the 349 malignant samples stained, observing
the different antibodies individually, 349 (100%) did
not stain for 34bE12 or p63, 230 (65.9%), and 270
(77.4%) were positive for MCT2 and AMACR, respec-
tively (Table III). From 203 benign prostatic TMA
samples stained, 189 (93.1%) stained for 34bE12 and
191 (96.7%) stained for p63. For AMACR and MCT2,
191 (94.1%) cases and 189 (93.1%) benign samples
were negative for AMACR and MCT2, respectively
(Table III).
From the 349 malignant prostatic samples classi-
fied as malignant lesions, 270 (77.4%) stained nega-
tively for 34bE12 and p63 and positively for AMACR
(Table IV). Using the criteria of one negative marker
(34bE12) plus two positive markers (AMACR/MCT2)
Fig. 2. Immunohistochemical expression of MCT2 (A^C),
AMACR (D^F), p63 (G^I), and 34bE12 (J^L) in normal prostate
tissue (NT),PIN lesions (PIN), andprostate tumor tissues (T).Main
pictures areat200magnificationandinsets areat400.
TABLE I. ExtensionofMCT2ExpressioninProstateCancerRelativetoGleasonScore
Gleason score No. of cases Positive cases
Extension of the staining
<5%þ 5% to 50%þ >50%þ
5 3 2 (0.8%) 0 0 2
6 83 55 (23.9%) 18 18 19
7 246 162 (70.4%) 23 35 104
8 17 11 (4.9%) 2 2 7
Total 349 230 (100%) 43 (18.7%) 55 (23.9%) 132 (57.4%)
TABLE II. ExtensionofAMACRExpressioninProstateCancerRelativetoGleasonScore
Gleason score No. of cases Positive cases
Extension of the staining
<5%þ 5% to 50%þ >50%þ
5 3 3 (1.1%) 0 1 2
6 83 62 (23%) 3 16 43
7 246 196 (72.6%) 21 52 123
8 17 9 (3.3%) 0 0 9
Total 349 270 (100%) 24 (8.9%) 69 (25.6%) 177 (65.5%)
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to identify a malignant lesion we have 327 of 349 ma-
lignant cases (87.7%) staining like a malignant lesion.
The same results were obtained when using p63 as
negative marker, that is, 87.7% of malignant cases
staining like a true malignant case.
We also calculated the specificity, positive predic-
tive value, and negative predictive value of the three
combinations. We observed that all have a specificity
and positive predictive value of 95.9% and 96.5% but
with the use of two negative markers and only one
positive marker we obtain a negative predictive value
of 69.3% whereas with both AMACR and MCT2 as
positive markers and only one negative marker, p63
or 34bE12, we can obtain a negative predictive value
of 89.6% or 89.7%, respectively (Table IV).
DISCUSSION
With the major effort to early detect prostate cancer
by men mass screening, there have been an increasing
number of small foci of cancer encountered in pros-
tate specimens. Inconclusive images on standard
H&E staining are occasionally encountered, implying
but not confirming the presence of malignancy. Such
findings are often described as ‘‘atypical foci’’ and in
most cases dictate a second biopsy [21–23].
It has been shown that using AMACR as a positive
marker in association with the traditional basal cell-
specific 34bE12 and/or p63 as negative markers can
help to confirm the diagnosis when small atypical
glands are identified by routine H&E staining [12,20].
It becomes more evident that it is crucial to use a com-
bination of positive and negative markers for immu-
nohistochemical analysis to assist in the diagnosis of
prostate cancer.
In the present study we analyzed the pattern of
expression of MCT2 and AMACR in a large number
of prostate cancer and benign prostate tissues to com-
pare the sensitivity and specificity of MCT2 to detect
prostate cancer when compared to AMACR, an
already established prostate cancer biomarker. Immu-
nohistochemistry revealed that like AMACR, MCT2 is
overexpressed in the majority of prostate cancer cases
with diverse pathologic characteristics. This overex-
pression occurs in virtually all Gleason grades with a
predominancy of diffuse overexpression, with more
than 50% of tumor stained in positive cases, meaning
that the positivity of MCT2 as well as AMACR is in-
dependent of the Gleason score, which is in accor-
dance with the data reported for AMACR [19].
Expression of MCT2 was comparable with
AMACR, allowing prostate cancer diagnosis in a min-
imal amount of tissue, giving few false-negative/
positive data.
When we observe the results of immunohistochem-
ical staining for the antibodies evaluated individually,
we noted that 34bE12 and p63 were the most sensitive
and specific markers to distinguish prostate cancer,
with 100% sensitivity for both and 93.1% and 94.1% of
specificity for 34bE12 and p63, respectively. However,
they are negative markers and there are many
limitations of using negative markers alone for the
TABLE III. SensitivityandSpecificity for theAntibodiesEvaluatedSeparately
34bE12 p63 AMACR MCT2 Total
True positive (malignant Cases) 349 349 270 230 349
True negative (benign cases) 189 191 191 189 203
Sensitivity (%) 100 100 77.4 65.9 —
Specificity (%) 93.1 94.1 94.1 93.1 —
Positive predictive value (%) 96.1 96.7 95.7 94.3 —
Negative predictive value (%) 100 100 70.7 61.4 —
TABLE IV. SensitivityandSpecificity for theAntibodiesEvaluatedinTripleCombinations
34bE12/p63/
AMACRþ
34bE12/MCT2 and/
or AMACRþ
p63/MCT2 and/
or AMACRþ Total
True positive (malignant cases) 270 327 327 349
True negative (benign cases) 179 189 191 203
Sensitivity (%) 77.4 87.7 87.7 —
Specificity (%) 88.2 93.1 94.1 —
Positive predictive value (%) 91.8 95.9 96.5 —
Negative predictive value (%) 69.3 89.6 89.7 —
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diagnosis of carcinoma, such as the fact that basal
cells could be patchy or discontinuous in some benign
lesions and lead to misdiagnosis. Consequently, nega-
tive staining for p63 or 34bE12 in a few glands sug-
gestive of cancer is not proof of their malignancy
since benign glands might not show uniform positivi-
ty with these markers.
Analyzing the results of immunohistochemical
staining for the antibodies evaluated in the triple com-
bination, we observed that the use of two positive
markers with one negative marker instead of one pos-
itive marker with two negative markers improves
the sensitivity to detect prostate cancer as well as the
negative predictive value, which was 69.3% using the
34bE12/p63/AMACR combination and 89.6% or
89.7% when using 34bE12/MCT2 and/or AMACR or
p63/MCT2 and/or AMACR. This result means that
with these combinations of markers, we decrease
the possibility of diagnosing benign prostate tissue as
prostate cancer.
The observation that similarly to AMACR, MCT2
also stains strongly in PIN lesions, if on one hand
decreases the specificity of these proteins, on the other
hand indicates that these two proteins may be in-
volved in tumor initiation. However, further studies
are needed to clarify the role of both markers on pros-
tate cancer initiation/progression.
CONCLUSIONS
Our study points to the consistent overexpression
of MCT2 in prostate cancer, which is comparable to
AMACR, an already established biomarker in pros-
tate cancer. Importantly, assessment of MCT2 togeth-
er with AMACR, along with the negative markers p63
and 34bE12, highly increases the accuracy in prostate
cancer diagnosis.
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